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Transcatheter arterial chemoembolisation (TACE) has been reported to be an efficient treatment of liver metastases of endocrine
tumours in short series of patients. However, several factors seem to affect its results. The aim of this work is to identify predictors of
response to TACE for liver metastases of endocrine tumours. A total of 163 TACE procedures were performed in 67 patients
between 1994 and 2004. Forty-four patients were treated with streptozotocin and 23 with doxorubicin. Primary tumour was located
in the pancreas for 19 patients, and had been removed in 43. Thirty-eight tumours were functioning. Response rate was 37%
(confidence interval [CI] 95%: 28–49%). Median time to progression (TTP) was 14.5 months (CI 95%: 9–41). In multivariate analysis
(n¼43), predictors of tumour response were body mass index (BMI) (odds ratio [OR]: 1.3; CI 95%: 1.04–1.63; P¼0.022),
functioning type of tumour (OR: 7.31; CI 95%: 1.26–42.5; P¼0.027), arterial phase enhancement on abdominal computed
tomography (CT) (OR: 8.11; CI 95%:1.06–62; P¼0.044) and use of streptozotocin for cytotoxic agent (OR: 21.3; CI 95%: 1.48–
306; P¼0.025). Analysis of TTP predictors showed that BMI (hazard ratio [HR]: 0.85; CI 95%: 0.76–0.86; P¼0.01) and arterial phase
enhancement (HR: 0.3; CI 95%: 0.12–0.73; P¼0.008) were associated with delayed progression. This large study confirms the
previously reported results of TACE regarding its efficacy for the treatment of liver metastases of endocrine tumours. Arterial phase
enhancement on abdominal CT and BMI are predictors of treatment’s efficacy. Streptozotocin should be the preferred cytotoxic
agent in order to save anthracycline for systemic chemotherapy.
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Endocrine tumours are rare tumours of the digestive tract (Modlin
et al, 2003; Warner, 2005). Their main feature is the secretion, by
some of them, of biologically active substances or hormones
responsible for typical syndromes and requiring a specific
management. Their prognosis is usually considered as being
favourable because of their slow-growing pattern, even though this
needs to be discussed according to several factors affecting
patients’ survival. Among these, the presence of liver metastases
is one of the most important (Madeira et al, 1998; Gullo et al, 2003;
Modlin et al, 2003; Plockinger et al, 2004).
First-line treatment is then surgery, as it is the only treatment
that allows a definite cure. However, in case of extensive
metastases, complete resection might be precluded. The aim of
therapy is then to control hormone-related symptoms and tumour
growth using different available approaches: somatostatin analo-
gues, interferon alpha, intravenous chemotherapy, peptide recep-
tor-targeted radiotherapy, vascular occlusive therapy and
transcatheter arterial chemoembolisation (TACE) (Mitry et al,
1999; Plockinger et al, 2004).
The rationale of TACE is to combine the effects of chemotherapy
injected in the hepatic artery, with those of anoxia induced by
hepatic artery embolisation (Ruszniewski and O’Toole, 2004).
Indeed, certain drugs are more efficient on anoxic cells (Roche,
1989) and reduced vascularisation can increase intratumoral drug
concentration and dwelling time in cancer cells (Bengmark et al,
1974; Delaunoit et al, 2004).
Transcatheter arterial chemoembolisation is effective to control
hormone-related symptoms in 70–100% of patients, especially in
those with carcinoid syndrome. Tumour response rate has widely
varied between 9 and 60% (Ruszniewski et al, 1993; Therasse et al,
1993; Diaco et al, 1995; Dominguez et al, 2000; Gupta et al, 2003;
Kress et al, 2003; O’Toole et al, 2003; Roche et al, 2003,
2004), partly explained by the limited case numbers (most studies
involve less than 35 patients) and presumably by some factors
related to the patients, their tumours, TACE protocol and previous
treatments.
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TACE for liver metastases of endocrine tumours in a large series of
patients.
PATIENTS AND METHODS
Patients
We conducted a retrospective bicentric study. Every patient with
liver metastases of endocrine tumours referred to Beaujon (n¼67)
or Ambroise Pare ´ (n¼13) Hospitals for TACE between 1994 and
2004 was recorded. Among these 80 patients, 67 were included in
our study. The remaining 13 patients were excluded because the
radiological documents were not available for re-evaluation.
Baseline clinical and radiological features listed in Table 1 were
recorded.
Concomitant use of somatostatin analogues was recorded when
patients were receiving long-term treatment, but not in case of
periprocedural administration. Indication for treatment was a
progressive disease before TACE, determined on two consecutives
abdominal computed tomography (CT) or magnetic resonance
imaging (MRI) procedures and confirmed on re-evaluation by an
experienced radiologist (MPV) according to RECIST criteria
(Therasse et al, 2000) or uncontrolled hormone-related symptoms
or an aggressive disease defined by extensive metastases (450%
replacement of liver parenchyma) and tumour-related symptoms.
Assessment of baseline radiological features relied on re-
evaluation by an experienced radiologist (MPV) blinded to
treatment outcome. In Beaujon Hospital, multiphasic helical CT
was performed with two consecutive CT machines. First, a CT
Twin Marconi (Haifa, Israel) was used (n¼42): unenhanced phase
(section thickness 5mm) was followed by enhanced study at late
arterial phase referred to as the pancreatic phase (section thickness
2.5mm, pitch 1.5) and during the portal venous phase (section
thickness 5mm, pitch 1.5) with a delay of 45 and 70s, respectively,
after initiation of the intravenous bolus injection of 100–120cc of
low osmolality contrast material iodine at a flow rate of 3cc/s.
Ingestion of water was obtained. During a second period, a General
Electric CT Light Speed Ultra (GE Healthcare, Milwaukee, WI,
USA) was used (n¼13): acquisition was performed with 1.25
section thickness. Reconstruction during the unenhanced phase
(section thickness 5mm, pitch 1.35), pancreatic phase (section
thickness 2.5mm, pitch 0.875) and the portal venous phase
(section thickness 5mm, pitch 0.875) were performed with a delay
of 45 and 70s, respectively, after initiation of the intravenous bolus
injection of 100–120cc of low osmolality contrast material iodine
at a flow rate of 3cc/s. Ingestion of water was obtained. In the
second institution (Ambroise Pare Hospital), a Twin Flash scanner
(Elscint, Haifa, Israel) was used (n¼6). Unenhanced phase
(section thickness 5mm) was followed by enhanced study at late
arterial phase referred to as the pancreatic phase (section thickness
2.5mm, pitch 1.5) and during the portal venous phase (section
thickness 5mm, pitch 1.5) with a delay of 45 and 70s, respectively,
after initiation of the intravenous bolus injection of 100–120 cc of
low osmolality contrast material iodine at a flow rate of 3cc/s.
The percentage of liver replacement was semiquantitatively
quoted (o25, 25–50, 50–75 and 475%). Arterial phase enhance-
ment was defined on the arterial phase images (when available) of
the pretreatment CT as a hyperattenuation of the lesion compared
to the adjacent liver parenchyma. No measure of the density was
performed. A heterogeneous pattern of the metastases was defined
as the presence of variously attenuating areas in a single lesion,
suggestive of necrosis, either before and/or after contrast medium
enhancement (arterial and/or portal phase).
Treatment
Intravenous hydration was started on 3h before TACE and
patients were premedicated with antibiotics. Cytotoxic drugs were
doxorubicin (50mgm
 2) or streptozotocin (1.5gm
 2). The latter
was chosen in case of pancreatic primary tumour or contra-
indication to anthracycline use. Patients with carcinoid tumours
were administered octreotide 200mg subcutaneously twice daily for
10 days beginning 24h before TACE to prevent carcinoid crisis. A
diagnostic superior mesenteric and celiac trunk arteriography was
first obtained to evaluate the distribution of hepatic arteries and
portal blood flow. Cytotoxic drug dissolved in normal saline was
combined with 10ml of iodized oil, and injected into the branches
of the hepatic artery distal to the gastroduodenal artery. This was
followed by embolisation with gelatin sponge particles until a
marked decrease in blood flow was observed. As injection of
streptozotocin containing mixtures has been reported to be painful
(Dominguez et al, 2000), probably in relation with its acidity,
procedures were then performed under general anaesthesia.
Treatment was repeated every 3 months. In case of objective
response or stable disease, usually after two procedures had been
performed, treatment could be temporarily interrupted until
symptomatic relapse or tumour progression.
Evaluation of tumour response
Follow-up evaluations were performed every 3 months. They were
based on clinical evaluation, tumour markers measurements when
available (Chromogranin A or specific marker) and tumour
Table 1 Baseline characteristics
Number of
available
data
Median age, years (range) 57 (25–82) 67
Male gender, n 36 67
Body mass index, median (range) 23.7 (13.2–33) 64
Performance status (ECOG), n 67
0–1 62
25
Functioning tumour, n 38 67
Primary lesion
Pancreatic location, n 19 67
Diameter (cm), median (range) 3 (0.8–16) 51
Resected, n 43 67
Extra-hepatic lesion(s), n 26 67
Indication of treatment, n 67
Progressive disease 41
Aggressive disease 9
Uncontrolled hormone-related symptoms 17
Previous chemotherapy, n 19 67
Concomitant treatment with somatostatin analogs, n 25 67
MIB-1 (%), median (range) 3 (1–60) 34
Radiological features of metastases
Longest diameter (cm), n 4 (1–14) 67
% of liver replaced by metastases, n 67
o25% 29
425 and o50% 14
450 and o75% 12
475% 12
Arterial phase enhancement, n 42 61
Heterogeneous pattern, n 45 62
Cytotoxic agent, n 67
Streptozotocin 44
Doxorubicin 23
Prognosis factors of chemoembolisation for endocrine tumours
F Marrache et al
50
British Journal of Cancer (2007) 96(1), 49–55 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sresponse assessment on CT or MRI. Originals CT or MRI films
were re-evaluated by an experienced radiologist (MPV). The
primary criterion of tumour response evaluation in this study was
that defined according the Response Evaluation Criteria in Solid
Tumors (RECIST) (Therasse et al, 2000): Complete response (CR)
was defined as the complete disappearance of all lesions; partial
response (PR) was defined as at least a 30% reduction in the sum
of the longest diameters of up to five target lesions, taking as a
reference the baseline sum of the longest diameters; progressive
disease (PD) was defined as at least a 20% increase in the sum of
the longest diameters or development of new lesions or global
deterioration of health status requiring treatment’s discontinuation.
Stable disease (SD) was defined as disease that showed neither
sufficient shrinkage nor increase to qualify as either PR or PD.
Date of progression was defined as the date criteria for PD are
met, taking as a reference the smallest measurements recorded
since treatment started. For patients whose treatment was
temporarily suspended, who had several periods of treatments,
date of progression was the date of the last evaluation
demonstrating PD before treatment’s failure. Duration of overall
response was defined as the time between the initial documented
response and the first date of recurrence or progression.
Clinical response evaluation could be retrospectively performed
in 23 patients and was based on the report of hormone-related
symptoms and symptomatic treatment in patients’ file. Complete
clinical response was defined as complete disappearance of all
hormone-related symptoms without any symptomatic treatment;
partial clinical response was defined as an improvement of
symptoms without any increase in symptomatic treatment or a
decrease of this treatment without any increase of symptoms.
Clinical progression was defined as an increase in hormone-related
symptoms or in symptomatic treatment. Clinically stable disease
was defined by the absence of modification of patient’s symptoms
and symptomatic treatment.
Biological response was evaluated in 38 patients based on
plasmatic chromogranin A level or any tumour-type-specific
marker when appropriate. Complete biological response was
defined as a complete normalisation of all tumour markers and
partial biological response was defined as a decrease of more than
50% compared to baseline level. Biological progression was
defined as an increase of 25% of any tumour marker and in case
tumour markers had neither increase or decrease sufficiently to
demonstrate biological progression or response, disease was
biologically stable.
When available, MIB-1 quantification performed either on
primary tumour or liver metastases was recorded from patients’
files.
Adverse effects related to the treatment were recorded from
patients’ files.
Statistics
The comparisons between tumour response according to RECIST
criteria and baseline characteristics of the patients were based on
w
2 and Fisher’s exact tests for qualitative variables, and on an
ANOVA for quantitative variables. Multivariate logistic regression
was then performed in order to identify the predictors of response
to treatment. A stepwise procedure with variables having a P-value
less than 0.25 in univariate analysis was used.
Time to progression (TTP) was measured from beginning of
treatment to date of progression, death, last follow-up, curative
surgery or liver transplantation. Overall survival (OS) was
measured from beginning of treatment to death or time of last
follow-up. The survival function was calculated with the method of
Kaplan–Meier. The differences of TTP according to baseline
characteristics were analysed using the log-rank test. Multivariate
analysis including variables with a P-value less than 0.25 was
subsequently performed using a Cox proportional hazards model
with a stepwise procedure. Differences were considered statistically
significant if the P-value was less than 0.05. All analyses were
performed using SAS version 9 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline characteristics
Baseline clinical and radiological features of the patients are shown
in Table 1. Transcatheter arterial chemoembolisation was
prompted by a progressive disease for 41 patients, by uncontrolled
hormone-related symptoms for 17 patients and by an aggressive
disease for the nine remaining ones. The primary lesion was
located in the small bowel (n¼24), the pancreas (n¼19), the
rectum (n¼4), the duodenum (n¼3), the appendix (n¼3),
the bronchus (n¼3), the stomach (n¼2), the kidney (n¼1) and
the large bowel (n¼1). In seven cases, no primary lesion was found.
Thirty-eight tumours were functioning. These were carcinoid
tumours (n¼31), gastrinomas (n¼2), VIPomas (n¼2), a
somatostatinoma, a calcitonin-secreting tumour and a PTHrp-
secreting tumour. Among these patients with functional tumours,
25 were treated with long-term somatostatin analogues. The other
patients had only minor and infrequent symptoms that did not
justify such therapy or tumour-type for which it was not relevant.
Four patients had poorly differentiated tumours. Liver metastases
were synchronous to the primary tumour in 58 patients. Twenty-
six patients had extra-hepatic lesions corresponding to the
unresected primary tumour and/or abdominal metastatic lymph
nodes in 13 of them. Fifteen patients had previously undergone
surgery for liver metastases and two pancreaticoduodenectomy.
One patient had multiple endocrine neoplasia type 1. Transcatheter
arterial chemoembolisation was performed with streptozotocin
in 44 patients, including 25 with non-pancreatic primary tumour,
but who received previously anthracycline chemotherapy (n¼10)
or had cardiac contra-indication to anthracycline (n¼15) among
which seven had severe carcinoid heart disease, requiring valvular
replacement in three cases.
Procedures
One hundred and sixty-three TACE procedures were performed
during 168 attempts. Median number of procedures per patient was
two, ranging from 1 to 8. Both hepatic lobes were treated in 138
cases, the right hepatic lobe in 20 cases and the left hepatic lobe
in three cases. Two procedures were performed without any
embolisation in relation with the presence of arterio-venous shunts.
Response to treatment
Complete or partial tumour response according to RECIST criteria
was observed in 37% (CI 95%: 28-49) of patients and 73% (CI 95%:
63–84) had CR, PR or SD, that is, a nonprogressive disease. The
median duration of overall response was 27 months (CI 95%:
12–67). Median TTP was 14.5 months (CI 95%: 9–41). Clinical
response was evaluated in 23 patients: 91% (CI 95%: 80–100)
responded, completely for 61% (CI 95%: 41–81). Complete results
about tumour, clinical and biological responses are shown in
Table 2 and Figure 1.
Predictors of tumour response
Identification of predictors of response to treatment was
performed by two means: by studying variables associated with
tumour response (complete or partial), or with TTP. Univariate
analysis of variables listed in Table 3 was performed. Variables
with a P-value o0.25 in these analyses were included in our
multivariate models, except MIB-1 for which too many data were
unavailable.
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response was performed in 43 patients. Body mass index (BMI)
(odds ratio: 1.3; CI 95%: 1.04–1.63; P¼0.022), functioning tumour
(odds ratio (OR): 7.31; confidence interval (CI) 95%: 1.26–42.5;
P¼0.027), arterial phase enhancement on computed tomography
(CT) (OR: 8.11; CI 95%: 1.06–62; P¼0.044) and use of
streptozotocin for cytotoxic agent (OR: 21.3; CI 95%: 1.48–306;
P¼0.025) were predictors of tumour response. There was no
significant interaction between these variables. Additionally, we
tested the following interactions: type of cytotoxic agent/primary
location, functioning type of tumour/primary location, BMI/
percentage of liver replacement, hypothesising a low BMI reflected
an advanced disease, and somatostatin analogues treatment with
all four of these identified factors. None of these interactions was
significant in our model. Figure 2 shows the tumour response rate
according to BMI category in our patients.
In the Cox proportional hazards model of variables associated
with TTP, 43 patients were included. Body mass index (HR: 0.85;
CI 95%: 0.76–0.86; P¼0.01) and arterial phase enhancement on
CT (HR: 0.3; CI 95%: 0.12–0.73; P¼0.008) were associated with
delayed progression (Figures 1 and 3). Interactions between these
variables, between each of them and somatostatin analogues
treatment, and between BMI and percentage of liver replacement
were not significant in this model.
Figure 1 Liver metastases of endocrine tumour showing a hypervascular pattern before treatment (left panel) that shrinked after chemoembolisation
(right panel).
Table 2 Clinical, biological and tumour responses (%)
Clinical
response
(n¼23)
Biological
response
(n¼38)
Tumour
response
(n¼67)
Complete response 61 18 1
Partial response 30 47 36
Stable disease 4.5 32 36
Progressive disease 4.5 3 27
Table 3 Univariate analysis of baseline characteristics according to tumour response and time to progression (TTP)
Tumour response TTP
Odds ratio 95% confidence interval P Hazard ratio 95% confidence interval P
Age
a 1.01 (0.97; 1.06) 0.587 0.98 (0.95; 1.01) 0.189
Gender (F vs M) 1.44 (0.53; 3.91) 0.468 0.74 (0.40; 1.39) 0.347
Body mass index
a 1.32 (0.99; 1.29) 0.069 0.86 (0.78; 0.95) 0.002
Pancreatic primary tumour 1.33 (0.45; 3.93) 0.610 1.11 (0.56; 2.17) 0.769
Functioning tumour 3.83 (1.27; 11.52) 0.016 0.72 (0.39; 1.33) 0.299
Primary lesion diameter
a 0.77 (0.57; 1.03) 0.08 1.14 (1.02; 1.28) 0.019
Resected primary lesion 0.76 (0.27; 2.18) 0.615 1.4 (0.75; 2.62) 0.287
Extra-hepatic lesion(s) 0.83 (0.30; 2.30) 0.716 1.6 (0.87; 2.96) 0.131
Previous chemotherapy 0.97 (0.32; 2.92) 0.96 1.75 (0.92; 3.35) 0.091
Progressive or aggressive disease 0.56 (0.20; 1.64) 0.284 1.37 (0.69; 2.74) 0.371
Concomitant treatment with somatostatin analogues 0.91 (0.33; 2.55) 0.864 1.27 (0.69; 2.35) 0.447
MIB-1
a 0.85 (0.67; 1.09) 0.197 1.04 (1.004; 1.069) 0.026
Hepatic lesion longest diameter
a 0.99 (0.97; 1) 0.22 1.01 (0.99; 1.01) 0.314
Liver replacement 450% 0.57 (0.20; 1.66) 0.305 1.98 (1.06; 3.70) 0.033
Arterial phase enhancement 2.55 (0.72; 9.02) 0.146 0.58 (0.3; 1.14) 0.115
Hepatic lesion homogeneous pattern 0.99 (0.31; 3.18) 0.985 0.87 (0.41; 1.87) 0.728
Streptozotocin vs doxorubicin 2.83 (0.88; 9.04) 0.073 0.997 (0.49; 2.02) 0.993
aQuantitative variables.
Prognosis factors of chemoembolisation for endocrine tumours
F Marrache et al
52
British Journal of Cancer (2007) 96(1), 49–55 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sSide effects
Side effects are listed in Table 4. No treatment-related death was
reported. The most common side effect was the post embolisation
syndrome, associating vomiting, abdominal pain and fever. One
patient had a liver abscess, whereas he had no previous story of biliary
anastomosis or portal vein obstruction. Three episodes of acute liver
failure followed treatment in two patients without carcinoid heart
disease or portal vein thrombosis, and whose percentage of liver
replacement was o50% and o75%, respectively. Each time, recovery
was complete. Five carcinoid crises occurred in two patients,
controlled with intravenous somatostatin analogues administration.
Survival
Median overall survival after beginning of treatment was 61
months (CI 95%: 30–86), and overall survival rates at 2 and 5 years
were 66 and 50%, respectively (Figure 4).
DISCUSSION
With a tumour response rate of 37% (CI 95%: 28–49%), our
results are in the range of previous studies regarding treatment’s
efficacy (Ruszniewski et al, 1993; Therasse et al, 1993; Diaco et al,
1995; Dominguez et al, 2000; Gupta et al, 2003; Kress et al, 2003;
O’Toole et al, 2003; Roche et al, 2003). Recently, Roche et al (2004)
reported a response rate of 74%, much higher than what we
observed. However, in this study, minor and objective responses
according to World Health Organization criteria for tumour
response were aggregated. Objective response rate, which corre-
lates with definition of response according RECIST criteria, was
40%, close to our findings.
A major pitfall of every clinical trial about endocrine tumours is
the lack of information regarding tumour progression, making end
points such as disease control or time to progression questionable.
In our series, 41 patients had documented progressive disease
so that it could be suggested that the remaining ones did not
have a progressive disease. To clarify this issue, it must be pointed
that among the remaining ones, nine had an aggressive disease
defined by X50% replacement of liver parenchyma. In
our univariate analysis of factors associated with time to
progression, this latter criterion appeared to be associated with
an earlier progression (P¼0.033, Table 3) and opposes the
assumption that these patients had a stable disease even without
TACE. Regarding the 17 other patients, their disease was not
documented as progressive and it is thus right to point that disease
control might be a debatable end point. This is the reason why
we designed our study of predictive factors based on two different
end points. The first one was tumour response (thus excluding
stable disease) based on radiological criteria, and the second
one was TTP.
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Figure 3 Predictors of time to progression (TTP). (A) Time to
progression according to the presence of arterial phase enhancement on
CT. (B) Distribution of TTP according to BMI.
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Figure 2 Tumour response rate according to BMI categories.
Table 4 Side effects
Side effects n
Post embolisation syndrome 79
Vagal reaction 8
Carcinoid crisis 5
Pulmonary embolism 3
Acute liver failure 3
Tumour lysis syndrome and acute renal failure 1
Stroke 1
Liver abscess 1
Coronary spastic angina 1
Grade III neutropaenia 1
Ascites 1
Prognosis factors of chemoembolisation for endocrine tumours
F Marrache et al
53
British Journal of Cancer (2007) 96(1), 49–55 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sAlthough the number of patients was somewhat limited, two
factors were found significant in both analyses: arterial phase
enhancement and BMI. As TTP could be an end point related to
the natural history of the disease, it could be hypothesised that
factors linked with it were in fact associated with the natural
history of the disease. However, these were also predictive of
radiological response, suggesting that any effect on time-related
end points would be at least partly related to a treatment effect. A
recent study by our group showed that microvessel density in
pancreatic endocrine tumours is correlated with the vascular
pattern of the tumour on helical CT (Rodallec et al, 2005).
Knowing this, it appears consistent that the more vascularised
the tumour, the better it responds to TACE. Although the CT were
performed on different machines in the two institutions, the
protocol of vascular opacification and the timing of images
acquisition remained the same, and this should not constitute a
significant bias in our study.
The other significant factor in both analyses was BMI. An
explanation could be that patients with a low BMI do not tolerate
treatment, although we did not find any evidence for the latter
hypothesis, or are those whose disease is the most aggressive. The
ECOG performance status might reflect tumour’s aggressiveness,
but statistical analysis could not be performed regarding this factor
as most of the patients were in good general condition, so that
only five had a performance status of 2. In addition, there was no
significant interaction in our model between BMI and percentage
of liver replacement, which could correlate with tumour aggres-
siveness. At last, the relation between BMI and tumour response
seems linear, suggesting the correlation we observed is not
exclusively imputable to a low response rate in the category of
patients with the lowest BMI. Regarding TTP, the role of BMI was
also significant but the type of relation could be different as in
patients with the highest BMI, TTP seems to begin decreasing. A
limit of these analyses was that BMI was recorded at the time of
treatment, neglecting its evolution, whereas the latter is an
important criterion of nutritional evaluation.
These results raise the interesting issue of BMI’s role. Few
studies focused on this issue. An elevated BMI is a risk factor for
the occurrence of several cancers (Moertel et al, 1980; Calle et al,
2003), and is associated with a higher relapse rate after surgical
treatment of colon, rectal and prostate cancer (Meyerhardt et al,
2003; Amling et al, 2004; Freedland et al, 2004; Meyerhardt et al,
2004). However, its impact on disease’s natural history and
response to treatment is less documented. A study about patients
with hormonal refractory prostate cancer showed a positive
correlation between BMI and survival (Halabi et al, 2005). It
may be suggested that a lower BMI reflects a more aggressive
disease, although this is difficult to define, and may refer to
tumour extension, tumour kinetic, tumour biology or treatment
sensitivity. The pathophysiological mechanisms involved are still
unknown, and a role for adipokines might be hypothesised
(Trayhurn and Wood, 2004). Other explanation could be
advanced: chemotherapy dose was based on body surface area
(mgm
 2) such that patients with higher BMI may receive a larger
total dose of chemotherapy. However, the chemotherapy was
delivered via the hepatic artery. If it is assumed that (i)
chemotherapy is selectively delivered to tumour vessels, (ii) there
may be some first passage extraction and (iii) subsequent
embolisation facilitates retention of drug in tumour, then the
volume of distribution of drug is not the same as when given i.v.
and is not a function of body surface area (except to the extent that
liver size relates to this). Thus (assuming that tumour size is not
correlated with BMI), the tumours of patients with higher BMI
would be exposed to higher concentrations of chemotherapy.
Assuming that chemotherapy has a dose–response effect, this may
account for the relationship between BMI and objective response
rate. This would also question the rationale of dosing according to
body surface area in this context.
Two other factors were associated with tumour response: the use
of streptozotocin, and the functionality of the tumour. However,
these two factors did not correlate with TTP, and their predictive
value must be taken cautiously. To account for this discrepancy, it
can be hypothesised that our cohort was not large enough to show
statistical significance for these factors in this peculiar model, or
that the reason arterial phase enhancement and BMI are associated
with TTP is not only their impact on tumour response but also
a potential role on tumour kinetic. Regarding this issue, it must
be stressed that MIB-1, which is a marker of cellular proliferation
studied by immunohistochemistry and a well-documented prog-
nosis factor (Chaudhry et al, 1992; Pelosi et al, 1996; Gentil Perret
et al, 1998), should have been integrated in our two multivariate
models according to univariate analyses, but, unfortunately, could
not, as the number of missing data was too elevated. To clarify
these questions, these factors, including MIB-1, should be studied,
if possible in a larger population, from the time of diagnosis, and
for BMI, followed-up.
As treatment assignment (streptozotocin vs doxorubicin) was
not controlled nor randomised, it is not possible to conclude that
streptozotocin is a more efficient drug. However, it suggests it is at
least as efficient. Based on this, we see a potential advantage in
using streptozotocin that is to save doxorubicin for subsequent use
and chemotherapy, delaying the time we will face cardiac toxicity
risk that sometimes hinders therapeutic strategy.
Efficacy of TACE does not seem to depend on the time it is
performed early or late during the course of the disease (28% of
patients had previously received chemotherapy), nor by the
presence of extra-hepatic lesions. This must be discussed knowing
half of the patients with extra-hepatic lesions had exclusively an
unresected primary lesion or abdominal metastatic lymph nodes,
and the others had a limited number of small lesions. The major
prognostic role of liver metastases prompted TACE in these
patients (Madeira et al, 1998; Gullo et al, 2003; Modlin et al, 2003;
Plockinger et al, 2004).
Severe adverse events occurred after 17 TACE procedures (10%),
but direct responsibility of treatment seems questionable for some
of them (stroke, pulmonary embolism, coronary spastic angina).
We did not observe any relation between baseline characteristics
and the occurrence of adverse events. Risk factors for TACE-
related adverse events have been described in studies focusing
on hepatocellular carcinoma (Chung et al, 1996) (portal vein
obstruction, biliary anastomosis or obstruction, compromised
functional hepatic reserve). Except two patients who had a
previous story of duodenopancreatectomy, none of our patients
had such risk factors. A recent study suggested that replacement of
more than 70% of liver by the tumour was associated with an
increased morbidity from treatment (Roche et al, 2004). We did
not confirm such findings, maybe in relation with the fact that
operators perform a less complete embolisation, injecting less
gelatin particles, in case of bulky disease.
Post embolisation syndrome was reported only after 47%
of procedures in our series, whereas its frequency is usually
reported to be higher (Ruszniewski et al, 1993; Therasse et al, 1993;
Diaco et al, 1995; Dominguez et al, 2000; Gupta et al, 2003; Kress
et al, 2003; O’Toole et al, 2003; Roche et al, 2003, 2004). We can
account for this discrepancy by assuming that as this side effect is
extremely frequent it was probably not systematically reported, so
that we recorded it only when considered significant, that is,
responsible for an extension of hospital stay or the use of major
analgesics.
In conclusion, this study confirms previously reported results
regarding TACE efficacy and tolerance for the treatment of liver
metastases of endocrine tumours in a large series of patients. Our
results suggest streptozotocin should be the drug of choice for
TACE, as it allows saving anthracyclines for subsequent intra-
venous chemotherapy. We have identified several predictors of
response to TACE, which should enable clinicians to better identify
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spatients that will have a stronger benefit from treatment. In
addition, the original association between BMI and response to
treatment, if confirmed in subsequent studies, would raise
interesting questions about its pathophysiological mechanisms.
Although this study is one of the largest focusing on this topic, the
number of patients included in the multivariate analysis remains
limited, emphasising the need for larger, prospective multicentre
studies in the future.
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